PD(L)-1 inhibitor therapy can thus provide a timeline therapeutic schedule for cancer patients (143), and restoring (or reactivation) of T-cell functionality mediated by such therapy can possibly be a winning step for beating SARS-CoV-2 infection (144). This evidence concerns the gene CD274 and cancer.